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Summary 
Herpesviral  DNA  fragments  isolated  from  AIDS-associated  Kaposi's  sarcoma  (KS)  tissue 
(KSHV-DNA)  share  homology with  two lymphotropic oncogenic ~-herpesviruses,  Epstein- 
Barr virus and Herpesvirus saimiri, and are present in the lesions of more than 95% of HIV and 
non-HIV-associated forms of KS, AIDS-related body cavity-based lymphomas, and AiDS-related 
multicentric  Castleman's  disease.  Here  we  show  that  BC-1,  a  KSHV-DNA-positive,  body 
cavity-based lymphoma cell line, produces infective herpesviral particles carrying a linear 270-kb 
genome that  specifically transmits  KSHV-DNA to  CD19 + B  cells.  Transmission  of KSHV- 
DNA is dependent upon a biologically active, replicating virus, since it is blocked by UV irra- 
diation and foscarnet, an inhibitor of viral DNA-polymerase. This study represents the first iso- 
lation and transmission of the human herpesvirus-8/KS-associated herpesvirus. 
T 
he  herpesviruses  (family  Herpesviridae)  are  double- 
stranded DNA enveloped viruses widely distributed in 
nature  that  are  implicated  in  many  human  diseases  (1). 
Herpesviral  DNA  fragments  recently  identified  in  AIDS- 
associated Kaposi's sarcoma  (KS)  tissue  (2-4)  (KS herpesvi- 
ral-like  DNA  [KSHV-DNA])  (5)  share  homology  with 
two lymphotropic oncogenic ~/-herpesviruses,  EBV (6)  and 
Herpesvirus saimiri  (HVS)  (7).  EBV is a B  cell-immortaliz- 
ing virus that is involved in the pathogenesis  of malignant 
lymphomas  (6).  HVS is  a  T  cell-immortalizing  virus  that 
can cause fulminant T  cell lymphomas (7).  The homology 
of KSHV-DNA with these viruses suggests that the newly 
identified  sequences  may belong to the  genome of a  new 
member  of the  herpesvirus  family  (1).  Although these  se- 
quences  were  first  identified  in  KS  tissue  (5,  8,  9),  and 
more  recently  in  other proliferative  diseases  (10,  11),  the 
role of the putative new herpesvirus in the pathogenesis of 
these disorders remains to be defined. Primary to this ques- 
tion  is  the  isolation  and  characterization  of the  putative 
KSHV-DNA virus. Here we show the first isolation of in- 
fective herpesviral particles  (human herpesvirus-8  [HHV-8/ 
KSHV])  that  specifically transmit  KSHV-DNA to normal 
circulating human B  cells. 
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Materials  and Methods 
Viral Preparation.  Viral pellets  were  obtained as described  in 
(12). Briefly, BC-1 cells (13) were collected at low-speed centri- 
fugation,  resuspended  in  1:20  vol  of media,  and  snap-frozen 
(cell-associated  virus extract).  To obtain supernatant virus pellets, 
postculture-conditioned media from BC-1  cells was  cleared  by 
centrifugation at  1,400 g 4~  filtered  through a 0.45-1xm mem- 
brane and centrifuged 2 h at 23,000 g at 4~  Pellets were resus- 
pended in 1:50 vol of media and snap-frozen in dry ice/ethanol. 
Both extracts  (cell or supernatant virus) were thawed and frozen 
and thawed  once more, sonicated 4  ￿  40 s in a cup sonicator 
(Heat Systems-Ultrasonics,  Inc., Plainview,  NY), and cleared  by 
centrifugation  at 10,000 g at 4~  To concentrate and further purify 
the viral preparations  (14), they were loaded over a 25% sucrose/ 
PBS (Ca  2+, Mg  2+) cushion and pelleted  by overnight centrifuga- 
tion at 70,000g at 4~  Viable BC-1 cells that might contaminate 
the preparation were excluded by passaging through a 0.45-~m 
filter  (supematant virus),  triple  freezing and thawing in the ab- 
sence of freezing agents, and extensive  sonication and centrifuga- 
tion at  10,000 g.  Furthermore,  the viral  isolates were examined 
for the presence of any contaminating cell by light  and electron 
microscopy, by culture in rich medium, and sensitivity to DNAse 
degradation of the cellular genep53 (see Fig. 1 A) matched with a 
control of viable BC-1 cells (not shown). 
Negative-staining Electron Microscopy.  Viral  pellets  were  resus- 
pended in PBS (Ca  2+, Mg2+),  and the virus  was absorbed onto 
parlodion/carbon-coated grids  using the agar diffusion  method, 
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an electron microscope (JEOL U.S.A. Inc., Peabody, MA). 
Pulse Field Gel Electrophoresis (PFGE) Analysis.  Cells (25 ￿  106/ 
rnl final) or cell viral pellets (corresponding to 2 ￿  108 cells) were 
molded into  0.9%  NaC1 low melting point agarose plugs. The 
plugs were incubated for 2 d at 50~  in lysis buffer (0.5 M EDTA, 
pH  8.0,  1%  sarkosyl,  1 mg/ml  proteinase K),  and washed  and 
stored in  0.5  M  EDTA  at  4~  PFGE was performed using a 
CHEF-DR II system (Bio Rad Laboratories, Richmond, CA) fol- 
lowing the manufacturer's instructions. Samples  were run on  1% 
PFGE-certified agarose (Bio Rad) gels in 0.5  ￿  Tris-borate-EDTA 
buffer at 200 V, initial A time =  3 s, final A time =  30 s, for 23 h at 
14~  PFGE Marker I ladder molecular weight marker plugs were 
obtained from Boehringer Mannheim Biochemicals (Indianapo- 
lis, IN). 
Southern Blot  for KSHV-DNA or EBV Sequences.  Gels were trans- 
ferred  to  nitrocellulose filters  and  probed  with  random  prime 
32p-labeled probes for KSHV-DNA (KSBam330 fragment [5]) or 
the EBV terminal repeat region (10,  13). 
PCR Detection of KSHV-DNA and p53.  Cells  were  pelleted 
and resuspended in 3 jxl PBS. Resuspended cells, or viral extracts 
(3  ~1), were treated with 30  I*1 of Genereleaser (Bio-Ventures, 
Mufreesboro, TN). The DNA was released in a thermocycler fol- 
lowing the manufacturer's protocol. Primers for KSBam 330233 or 
for p53 (5) were added to one third of the DNA, and a PCR re- 
action was carried out in a thermocycler as described (5). 
DNAse Treatment of the Viral Isolates.  Before  PCR,  viral  ex- 
tracts  were  treated  with  RNAse-free  DNAase  I  (Boehringer 
Mannheim) for 15 rain following the manufacturer's conditions. 
Itfeaion  Studies.  Umbilical  cord  blood  mononuclear  cells 
(CBMC) obtained by Ficoll centrifugation were incubated for 40 
rain at room temperature with viral extracts at a cell density of 
107 cells/ml, washed once with media to remove excess virus, re- 
suspended in RPMI,  20%  FCS, 20%  CD34-derived spindle cell 
(Rafii, S., E.A. Mesri, and A.S. Asch, unpublished data)  condi- 
tioned media (RC-20 medium) at a density of 106 cells/m], and 
incubated during a week. For PCR,  one-third of the cells were 
harvested, washed once  with media, and treated with  Genere- 
leaser. 
UV Irradiation of the Viral Preparations.  Viral pellets resuspended 
in PBS or media were exposed to a dose of 9 mJ of UV light us- 
ing a Stratalinker (Stratagene, La Jolla, CA). 
Enrichment in  CD19 Cells and Immunodepletion of CD19 Ceils. 
B  cells were immunoselected from CBMC  using an anti-CD19 
mAb coupled to magnetic beads (Dynabeads; Dynal, Lake Suc- 
cess, NY) following the manufacturer's conditions. A similar pro- 
cedure repeated three times was used to deplete the CBMC of B 
cells. 
Effect of Foscarnet.  Infected cells were incubated in the presence 
of different doses of Foscamet (Foscavir; Astra, Westborough, MA). 
Results 
We  used methods  for herpesviral preparation and  con- 
centration  to  obtain  viral  particles  from  BC-1  cells,  an 
AIDS-related, body  cavity-based lymphoma  (BCBL)  cell 
line that stably carries KSHV-DNA  (13). We obtained su- 
crose  cushion  purified  cell-free pellets  (see  Materials  and 
Methods)  that  were  KSHV-DNA-positive by PCI<  from 
both BC-1  cells and their supernatants  (Fig.  1 A). KSHV- 
DNA present in the viral preparations within a viral capsid 
should  be  resistant  to  DNAse  degradation,  whereas  free 
DNA should be sensitive. Fig. 1 A  shows the results of the 
DNAse sensitivity assay of KSHV-DNA from viral isolates. 
As an internal control for free (nonencapsidated) DNA, we 
used the detection of the cellular gene p53, present in free 
BC-1 cellular genomic DNA which is also found in the viral 
preparations. When  the pellets were  treated with DNAse, 
the p53 gene could no longer be detected by PC1L. In con- 
trast,  KSHV-DNA  in the  viral isolates is DNAse  resistant 
and can be amplified by PCR  after DNAse treatment (Fig. 
1), indicating that the KSHV-DNA is protected, quite pos- 
sibly inside a viral capsid. To show that DNAse protection 
of viral genes  was  not  limited to  this  KSHV-DNA  frag- 
ment (KS330Bam)  and its immediately adjacent region, we 
also carried out a similar analysis with a viral gene adjacent 
to the other reported KSHV fragment (KS631Bam;  [5] that 
was  recently  cloned  and  is  distant  from  KSHV330Bam 
(Cesarman,  E.,  R.  Nador,  and D.M.  Knowles, manuscript 
in preparation).  We  found  that  this KSHV  gene  was  also 
protected from DNAse degradation (data not shown). 
To  further  characterize  the  viral  preparation,  we  per- 
formed negative-staining electron microscopy that showed 
the presence of several virus-like particles (Fig. 1 B). While 
none of these particles allows unequivocal identification as 
a  herpesvirus,  they have  features  of the  herpesviruses  and 
similarly appearing particles are characteristic of herpesviral 
preparations (15). No intact cells or other cellular organelles 
were seen in these preparations. 
PFGE  of the  viral preparations  (Fig.  1  C)  showed  that 
KSHV-DNA  belongs  to  a  linear 270-kb  genome  present 
both in BC-1  cells (16)  and in the viral pellet. In contrast, 
EBV,  also produced by BC-I  cells (13),  hybridizes with a 
170-kb  genome.  Our  results show  that  in  the  BC-1  viral 
isolates, KSHV-DNA  is contained in a viral genome that is 
distinct from the EBV genome.  The DNAse protection of 
distant  segements  of the  270-kb  KSHV-DNA  viral  ge- 
nome, in contrast with the DNAse sensitivity of nonvirally 
associated genes and the presence of herpesviral-like parti- 
cles in the isolates, are consistent with encapsidation of the 
KSHV-DNA viral genome. 
To  determine whether  the virus carrying KSHV-DNA 
was infective, we tested the viral preparations for their ca- 
pacity to infect CBMC.  Fig. 2  A  shows viral transmission 
of KSHV-DNA  to  CBMC  after  1 wk of exposure to  the 
viral isolates. The figure further shows that UV irradiation 
of the  viral  extracts  abolishes  KSHV-DNA  transmission 
without modifying its ability to act as a PCR. template. Since 
this dose of UV irradiation is known to inactivate herpesvi- 
ral DNA  replication and transcription, our results indicate 
that transmission of KSHV-DNA is accomplished by trans- 
mission in an active herpesvirus, HHV-8/KSHV. 
A  recent report notes that KSHV-DNA  is not present in 
AIDS-KS spindle cell lines, but is found in the CD19 B  cell 
compartment of KS patients (17). This finding and the fact 
that KSHV-DNA is present in the neoplastic cells of BCBL 
(10, 13) strongly suggest that HHV-8/KSHV  may be a lym- 
photropic virus possibly targeting the B  cell compartment. 
To  establish whether  HHV-8/KSHV  is  a  B  cell-specific 
virus,  we  used  immunoselection  techniques  to  positively 
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from BC-1  cells and supernatants. (A) DNAase protection 
analysis  of KSHV-DNA: PCR analysis of the viral pellets 
to detect KSHV-DNA and p53. Left panel, before DNAase 
treatment; tight  panel, after incubation with DNAase I; lane 
1, no cells added; lane 2, PH3-1L1  cells (negative control); 
lane 3, BC-1  cell-associated viral  pellet; lane 4, BC-1  su- 
pernatant viral pellet; lane 5, BC-1 DNA. The KSHV and 
p53 arrows indicate the positions of the KS330Bam PCK 
product of 233 bp (5) and the p53  PCR product, respec- 
tively (5).  (B) Negative-staining EM of viral pellets shown 
at  ￿  (C)  PFGE and Southern blot analysis of the 
viral isolate.  High molecular weight DNA from BC-1 cells 
(EBV  +,  KSHV-DNA+),  P3H-R.1  cells  (EBV+),  and  the 
cell viral  pellet from BC-1  cells  was separated by PFGE 
and analyzed by Southern blot for the presence of EBV or 
KSHV-DNA sequences. 
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KSHV-DNA  to  cord  blood  B 
cells: inhibition  by  UV  irradia- 
tion  and  foscamet.  (A)  Viral 
transmission  of KSHV-DNA to 
cord  blood  mononuclear  cells. 
Lane  1,  mock-infected CBMC; 
lanes 2-6, CBMCs were infected 
with  cell-associated  (lanes 2-4) 
or supernatant  (lanes 5 and 6) vi- 
res;  lanes 3-6,  cells  were  ana- 
lyzed  1 wk after  infection;  lane 
2, cells were analyzed 2 wk after 
infection;  lanes  4  and  6,  virus 
was  irradiated  with  UV  light; 
lanes 7-10, PCR of the viral iso- 
lates; lanes  7 and  8,  cell-associ- 
ated virus; lanes 9 and  10, super- 
natant  virus; lanes 8 and  10, the 
viral  extract  was  irradiated  with 
UV  before  PCR.  Upper panel, 
KSHV-DNA PCR,  lower  panel, 
p53 PCR.  (B) Viral transmission 
of  KSHV-DNA  to  CD19  +  B 
cells.  Lane  1,  P3H-R1  cells 
(negative control); lane 2, Gene- 
releaser; lane 3, BC-1 cells (posi- 
tive control);  lanes 4 and 5, total 
CBMC;  lanes  6 and  7,  CDI9  + 
cells;  lanes  8  and  9,  B  cell- 
depleted CBMCs; lanes 4, 6, and 
8, active virus; lanes 6,  7, and  9, 
virus  irradiated  with  UV.  The 
left  panel  shows  the  analysis of 
the PCR products  on an agarose 
gel, the right panel shows the re- 
sult  of the Southern  blot of the 
same  gel  hybridized  with  the 
KSHV-DNA internal probe (5,  10, 13); in all cases, the PCR was positive for p53 (not shown). 
(C) CBMC infected with cell KSHV were cultured for 1 wk with or without the addition of(),  1, 
10, and 100 p~g/ml foscarnet (lanes 4-7, respectively). M, molecular weight markers; lane  1, P3H- 
ILl cells (negative control); lane 2, BC-1 cells (positive control); lane 3, CBMC infected with vi- 
rus irradiated with 9 mJ of UV light. In all cases, the PCR were positive for p53. The KSHV and 
p53 arrows indicate  the positions of the KSBam330 PCR product  of 233 bp and the p53 PCR 
product,  respectively (5). 
select CD19 +  (Pan-B)  ceils from cord blood and to deplete 
cord blood mononuclear  ceils of CD19 +  cells.  The  results 
in Fig. 2  B show that the preselected CD19-positive CBMCs 
were infectable with KSHV, while CD19-depleted  CBMC 
were  not  infected.  These  results  indicate  that  HHV-8/ 
KSHV is a B-lymphotropic herpesvirus. 
Foscarnet  is  a  specific  inhibitor  of  herpesviral  DNA 
polymerase  (18).  Its potential benefit as a  therapeutic  agent 
for AIDS-KS may be of importance  (19,  20).  The results in 
Fig. 2  C  show that foscarnet has an inhibitory effect on the 
transmission  of KSHV-DNA  to CBMC,  further reinforcing 
the  concept  that  transmission  and  persistence  of KSHV- 
DNA  depends  on a replication-competent herpesvirus. 
Discussion 
Our  data  demonstrate  that  the  herpesviral  DNA  frag- 
ments  associated  with  KS  and  BCBL  are  part  of a  new 
transmissible  B-lymphotropic  herpesvirus.  We  favor its de- 
nomination  as  human  herpesvirus-8  instead  of the  former 
descriptive  name  of Kaposi's  sarcoma-associated  herpesvi- 
rus  (5)  because  it is also  associated with BCBL  and  AIDS- 
related multicentric  Castleman's  disease  (10).  Genetic stud- 
ies  show  that  HHV-8/KSHV  is  a  virus  of the  subfamily 
Gammaherpesvirinae,  and  it  is  the  first  human  virus  of the 
genus  Rhadinovirus  (16);  studies  also  show  that  KSHV- 
DNA  is part of a viral genome that is collinear to Herpesvi- 
rus saimiri (Cesarman  et al., manuscript  in preparation). 
Although  it  has  been  found  in  a  few  other  tumors  (4, 
21),  the  very  strong  association  found  between  KSHV- 
DNA  and KS (5, 8, 9), KSHV-DNA  and the unique effusion 
phenotype  of BCBL  AIDS  lymphomas  (10),  and  KSHV- 
DNA  and  AIDS-related  multicentric  Castleman's  disease 
(11)  suggests  that  an  infectious,  HHV-8/KSHV-related 
lymphoproliferative  or inflammatory  component  could  be 
common  to  these  malignancies.  The  pattern  of HHV-8/ 
2388  Isolation and Transmission of HHV-8/KSHV KSHV  gene  expression  (Cesarman  et  al.,  manuscript  in 
preparation)  and  KSHV-DNA  amplification  found  in 
AIDS KS and BCBL  (5,  10)  indicates a  productive infec- 
tion in the lesions suggesting that HHV-8/KSHV  may play 
an active role in direct or immune-mediated pathogenesis. 
Moreover,  a  recent  report  shows  that  the  appearance  of 
HHV-8-infected  cells in the peripheral blood predisposes 
for  the  development  of KS  in  HIV-infected  individuals 
(22).  It  is  therefore  possible that  agents  that  can  impede 
HHV-8/KSHV  replication or infection (such as foscarnet) 
might be useful in preventing or ameliorating the course of 
these  disorders (19,  20).  Our findings raise the  possibility 
that  HHV-8/KSHV-infected  B  cells  play  a  role  in  the 
pathogenesis of KS. Further studies defining the biology of 
HHV-8/KSHV  and how  it can modify the phenotype of 
infected B  cells in the context of HIV infection (3,  4,  23) 
would provide important insights on  the pathophysiology 
of KS  and  other AIDS-associated malignancies,  and  they 
may  establish the  potential of HHV-8/KSHV  as  a  thera- 
peutic target for these disorders. 
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